US FDA approves Octapharma's Wilate for von Willebrand disease
This article was originally published in Scrip
Executive Summary
The US FDA has approved Octapharma's Wilate for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD), as well as in patients with mild or moderate VWD in whom the use of desmopressin – a standard of care that acts by promoting the release of von Willebrand factor – is known or suspected to be ineffective or contraindicated. The product will be launched next year.